Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 24;10(17):3773.
doi: 10.3390/jcm10173773.

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives

Elena Treppo  1 , Marco Binutti  1 , Roberto Agarinis  1 , Salvatore De Vita  1 , Luca Quartuccio  1
Affiliations
Review

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives

Elena Treppo et al. J Clin Med. .

Abstract

Antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation of the vascular wall. The pathogenesis of AAV is strongly associated with B cell-derived ANCAs; thus, Rituximab (RTX) has become a promising drug in the induction and maintenance treatment of AAV. The purpose of this review is to describe the efficacy and safety of RTX in the induction of remission and maintenance therapy of AAV. Herein, we summarize the randomized controlled trials that have contributed to the refinement of the use of RTX in AAV in the past decades. RTX has been proven to be effective both in new-onset disease and in relapsing disease. Although the optimal duration of AAV maintenance therapy remains unknown, the ANCAs and the B-cell repopulation may offer support for the administration of further RTX cycles (or not). The safety of RTX is comparable with cyclophosphamide, with the advantage of a low risk of malignancy and no concern for fertility. In conclusion, RTX now plays an important role in the induction and maintenance therapy of AAV. Optimizing RTX-based treatment strategies in AAV is one of the main goals of the current research in AAV.

Keywords: ANCA; B cell; rituximab; vasculitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Major drivers, PROS, and CONS for choosing RTX in AVV. Legend: PR3, proteinase 3; CYC, cyclophosphamide; PEX, plasma exchange.
See this image and copyright information in PMC

References

    1. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., Flores-Suarez L.F., Gross W.L., Guillevin L., Hagen E.C., et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11. doi: 10.1002/art.37715. - DOI - PubMed
    1. Geetha D., Jefferson J.A. ANCA-Associated Vasculitis: Core Curriculum 2020. Am. J. Kidney Dis. 2020;75:124–137. doi: 10.1053/j.ajkd.2019.04.031. - DOI - PubMed
    1. Salvador F. ANCA Associated Vasculitis. Eur. J. Intern. Med. 2020;74:18–28. doi: 10.1016/j.ejim.2020.01.011. - DOI - PubMed
    1. Berti A., Dejaco C. Update on the Epidemiology, Risk Factors, and Outcomes of Systemic Vasculitides. Best Pr. Res. Clin. Rheumatol. 2018;32:271–294. doi: 10.1016/j.berh.2018.09.001. - DOI - PubMed
    1. Mohammad A.J., Jacobsson L.T.H., Mahr A.D., Sturfelt G., Segelmark M. Prevalence of Wegener’s Granulomatosis, Microscopic Polyangiitis, Polyarteritis Nodosa and Churg-Strauss Syndrome within a Defined Population in Southern Sweden. Rheumatology. 2007;46:1329–1337. doi: 10.1093/rheumatology/kem107. - DOI - PubMed

LinkOut - more resources